Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Eledon Pharmaceuticals reported promising results from its Phase 1b trial evaluating tegoprubart for kidney transplant patients. Three participants demonstrated no acute rejection incidents at 56, 154, and 232 days post-transplant, with mean eGFRs above 70 mL/min/1.73m2. The Phase 2a IgAN study also indicated that tegoprubart was safe and well-tolerated, with no serious adverse events. The trial, which includes up to 12 participants across multiple countries, aims to characterize the pharmacokinetics and safety of tegoprubart. Eledon remains optimistic about the drug's potential to enhance kidney transplant outcomes.
Eledon Pharmaceuticals reported significant financial losses for Q4 and the full year 2022, with a net loss of $58.4 million ($4.09 per share) for Q4 and $88.0 million ($6.16 per share) for the year. Notably, the losses included a non-cash goodwill impairment charge of $48.6 million. The company is concentrating its resources on kidney transplantation programs, highlighted by the Phase 1b kidney transplant trial, where data will be shared at the World Congress of Nephrology. Cash reserves of approximately $56.4 million are expected to sustain operations into Q1 2024.